Selective and noncovalent targeting of RAS mutants for inhibition and degradation

Activating mutants of RAS are commonly found in human cancers, but to date selective targeting of RAS in the clinic has been limited to KRAS(G12C) through covalent inhibitors. Here, we report a monobody, termed 12VC1, that recognizes the active state of both KRAS(G12V) and KRAS(G12C) up to 400-times...

Descripción completa

Detalles Bibliográficos
Autores principales: Teng, Kai Wen, Tsai, Steven T., Hattori, Takamitsu, Fedele, Carmine, Koide, Akiko, Yang, Chao, Hou, Xuben, Zhang, Yingkai, Neel, Benjamin G., O’Bryan, John P., Koide, Shohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113534/
https://www.ncbi.nlm.nih.gov/pubmed/33976200
http://dx.doi.org/10.1038/s41467-021-22969-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113534/
https://www.ncbi.nlm.nih.gov/pubmed/33976200
http://dx.doi.org/10.1038/s41467-021-22969-5

Ejemplares similares